Craft

Assertio

Stock Price

$3.3

2023-08-30

Market Capitalization

$304.5 M

2023-08-30

Revenue

$156.2 M

FY, 2022

Assertio Summary

Company Summary

Overview
Assertio (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. It offers INDOCIN, a non-steroidal anti-inflammatory drug, and CAMBIA, a prescription medicine used to treat migraine attacks. In addition, the company provides ZIPSOR, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults, and SPRIX, a solution for the management of moderate to moderately severe pain that requires analgesia at the opioid level.
Type
Public
Status
Active
Founded
1995
HQ
Lake Forest, IL, US | view all locations
Website
https://www.assertiotx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Dan A Peisert

    Dan A Peisert, President, Chief Executive Officer, Director

  • Jeff Christensen

    Jeff Christensen, Senior Vice President, Commercial

  • Sam Schlessinger

    Sam Schlessinger, Vice President, Legal

  • Ajay Patel

    Ajay Patel, Senior Vice President, Chief Accounting Officer

Operating MetricsView all

Patents (US)

12
47.8%

FY, 2020

Products

8
60.0%

FY, 2020

Trademarks

15

May, 2021

LocationsView all

1 location detected

  • Lake Forest, IL HQ

    United States

    Landmark of Lake Forest, 100 Saunders Rd Ste 300

Assertio Financials

Summary Financials

Revenue (Q2, 2023)
$41.0M
Net income (Q2, 2023)
$8.5M
Cash (Q2, 2023)
$70.2M
EBIT (Q2, 2023)
$12.4M
Enterprise value
$272.5M

Footer menu